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The goal of this study was to evaluate the time course of metabolic changes in leukaemia cells treated with the Bcr-Abl tyrosine
kinase inhibitor imatinib. Human Bcr-Abl
þ K562 cells were incubated with imatinib in a dose-escalating manner (starting at 0.1mM
with a weekly increase of 0.1mM imatinib) for up to 5 weeks. Nuclear magnetic resonance spectroscopy and liquid-chromatography
mass spectrometry were performed to assess a global metabolic profile, including glucose metabolism, energy state, lipid metabolism
and drug uptake, after incubation with imatinib. Initially, imatinib treatment completely inhibited the activity of Bcr-Abl tyrosine kinase,
followed by the inhibition of cell glycolytic activity and glucose uptake. This was accompanied by the increased mitochondrial activity
and energy production. With escalating imatinib doses, the process of cell death rapidly progressed. Phosphocreatine and NAD
þ
concentrations began to decrease, and mitochondrial activity, as well as the glycolysis rate, was further reduced. Subsequently, the
synthesis of lipids as necessary membrane precursors for apoptotic bodies was accelerated. The concentrations of the Kennedy
pathway intermediates, phosphocholine and phosphatidylcholine, were reduced. After 4 weeks of exposure to imatinib, the
secondary necrosis associated with decrease in the mitochondrial and glycolytic activity occurred and was followed by a shutdown of
energy production and cell death. In conclusion, monitoring of metabolic changes in cells exposed to novel signal transduction
modulators supplements molecular findings and provides further mechanistic insights into longitudinal changes of the mitochondrial
and glycolytic pathways of oncogenesis.
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Chronic myeloid leukaemia (CML) is a clonal myeloproliferative
disorder that is characterised by excessive production and
premature release of myeloid cells. The molecular hallmark of
CML is the Philadelphia (Ph) chromosome that results from the
t(9;22) q(34;11) reciprocal chromosomal translocation. The Ph
chromosome contains the BCR-ABL hybrid gene (Nowell and
Hungerford, 1960; Rowley, 1973) that encodes an oncogenic fusion
protein, Bcr-Abl, of 190, 210 and 230kDa (Heisterkamp et al,
1983). The fusion proteins possess a constitutively active cyto-
plasmic Abl tyrosine kinase domain that does not block
differentiation, but enhances the proliferation and viability of
myeloid cells. Furthermore, Bcr-Abl tyrosine kinase protects
haematopoietic progenitor cells from spontaneous apoptosis as
well as from that induced, for example, by chemotherapeutic drugs
(Bedi et al, 1995). Although the precise mechanism by which
Bcr-Abl exercises its antiapoptotic properties is unknown, several
possible explanations have been reported, including increased
expression of the antiapoptotic protein, Bcl-xL (Amarante-Mendes
et al, 1998) and induction of the nuclear factor-kB (Reuther et al,
1998).
Targeting the tyrosine kinase activity of Bcr-Abl is an attractive
therapeutic strategy in CML. Several tyrosine kinase inhibitors,
such as imatinib mesylate (CGP57148B or Gleevec, Novartis
Pharma, Basel, Switzerland), have been developed. Imatinib
competitively inhibits the binding of ATP to the kinase domain
of the Abl at low micromolar concentrations (Druker et al, 1996;
Buchdunger et al, 2000). Its binding abrogates the activity of the
Bcr-Abl oncoprotein through the inhibition of Bcr-Abl auto-
phosphorylation and substrate phosphorylation leading to the
inhibition of cell proliferation and induction of apoptosis (Druker
et al, 1996; Deininger et al, 1997; Gambacorti-Passerini et al, 1997).
Nuclear magnetic resonance (NMR) spectroscopy has success-
fully been used as a tool to evaluate the efficacy of anticancer
therapies on the basis of the altered metabolic oncogenesis
network (Evelhoch et al, 2000; Gillies et al, 2000). It is a technique
that yields metabolic and bioenergetics information from cells or
tissues in a dynamic manner, and can be applied non-invasively
in vivo. For example, variations in the rate of cell proliferation,
cell-cycle progression and apoptosis cause changes in glucose cell
metabolism and energy state (Evelhoch et al, 2000; Gillies et al,
2000; Griffin and Shockcor, 2004). Moreover, the metabolic
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sresponse to anticancer treatment resulting in apoptosis and
necrosis through the specific inhibition of a signal transduction
pathway often occurs before morphological or histological changes
are evident (Shih et al, 2005). Thus, a large number of reported
metabolic changes involved in apoptotic processes, such as an
increased concentration of polyunsaturated fatty acids (PUFAs;
Blankenberg et al, 1996; Robertson and Orrenius, 2000; Griffin
et al, 2003) and triacylglycerol (TAG; Blankenberg et al, 1997;
Al-Saffar et al, 2002), as well as changes in choline-containing
metabolites from the Kennedy pathway, such as choline, phos-
phocholine (PC) and glycero-PC (GPC; Glunde et al, 2002; Valonen
et al, 2005), can easily be observed by
1H- and
31P-NMR.
In this study, we investigated the early and late biochemical and
molecular events taking place during imatinib-induced apoptosis in
human leukaemia K562 cells. Metabolic
1H-,
13C- and
31P-NMR were
used for detection of changes in oncogenesis-related metabolic
pathways, such as phospholipid, glucose and energy metabolism.
The changes in metabolite patterns were correlated with the changes
in protein expression and intracellular imatinib concentrations.
MATERIALS AND METHODS
Cell culture and imatinib treatment
The human Bcr-Abl
þ leukaemia cell line, K562, was purchased
from the German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). The cells were grown in an
RPMI 1640 culture medium containing 10% foetal bovine serum
(FBS) and were kept at 371C with 95% air/5% CO2. Imatinib was
kindly provided by Dr Buchdunger (Novartis Pharma, Basel,
Switzerland). The K562 cells were treated with increasing
concentrations of imatinib (increase of 0.1mM per week), whereas
the control cells were kept under the same conditions without the
addition of imatinib. The medium containing fresh imatinib was
changed at the beginning of the new treatment period and at the
beginning of every feeding/subcultivation cycle. The dose esca-
lation of 0.1mM imatinib per week has been chosen on the basis
of previously published protocols (Mahon et al, 2000; Melo and
Chuah, 2007), in which leukaemia cells, such as K562, were
exposed to increasing concentrations of imatinib to induce
resistance against 1mM imatinib. The increments of imatinib
increase were kept low at 0.1mM per week to ensure that the cells
were able to adapt to the changing conditions while still exhibiting
metabolic response to drug exposure. Cell extracts, lipids and
media fractions were collected and analysed by NMR after 96h,
1 (0.1mM), 2 (0.2mM) and 4 weeks (0.4mM imatinib).
Cell proliferation and viability were examined by cell counting
using the trypan blue exclusion method.
Western blot assay of phospho-tyrosine kinase expression
Phospho-tyrosine kinase activity was assessed by western blot
analysis. Protein lysates were analysed by electrophoresis on
7–14% SDS–PAGE gels, and blotted onto polyvinylidene difluo-
ride membranes by semidry electrophoretic transfer. The gel was
then stained with Coomassie Blue. The membrane was blocked
with 3% dry milk and 0.1% Tween 20 in PBS and incubated with
primary antibodies (4G10 antiphosphotyrosine and b-actin, Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The filters were
washed and incubated with horseradish peroxidase-conjugated
donkey antirabbit antibody, and quantities of proteins relative to
b-actin were determined by densiometry.
Flow cytometry analysis on apoptosis Abl and
p-glycoprotein
To compare protein expression levels, the cells were washed, fixed,
permeabilised and stained with the following antibodies: anti-Abl
(Cell Signaling Technology Inc., Beverly, MA, USA), anti-p-
glycoprotein (MRK16, Alexis Biochemicals, San Diego, CA, USA)
and anti-Glut-1 (Dako Cytomation, Carpinteria, CA, USA). The
mean fluorescence intensity (x-mean all) of control and treated
cells was used for the quantification of protein expression. For
measurements of apoptosis and necrosis, the cells were incubated
with a YoPro-1/PI dye (Molecular Probes, Eugene, OR, USA). The
analysis was performed by using either a Becton Dickinson
FACSCalibur (Franklin Lakes, NJ, USA) or by using a Beckman
Coulter FC500 (Brea, CA, USA) instrument at the Flow Cytometry
Cancer Core Facility, University of Colorado, Denver.
Cell extraction for NMR spectroscopy
For NMR experiments, the cells (B10
8) were incubated with
5mmoll
 1 [1-
13C]glucose (Cambridge Isotope Laboratories,
Andover, MA, USA) for the last 4h of treatment before perchloric
acid (PCA) extraction. All cell extractions were performed using a
previously published PCA extraction protocol (Gottschalk et al,
2004). Lyophilised PCA cell extracts were redissolved in 0.6ml and
media in 1ml of deuterium oxide. After centrifugation, the
supernatants were neutralised to pH 7.2 to allow for precise
chemical shift assignments. Lipid extracts were redissolved in 1ml
mixture of deuterated methanol/chloroform (2:1, v/v).
NMR spectroscopy experiments
All high-resolution
1H- and
13C-NMR experiments were performed
using a Bruker 500MHz DRX spectrometer equipped with an
inverse 5-mm TXI probe (Bruker BioSpin, Fremont, CA, USA). All
31P-NMR experiments were performed using a 300MHz Bruker
Avance system with a 5-mm QNP probe. For proton NMR, a
standard water presaturation pulse programme was used for water
suppression; spectra were obtained at 12p.p.m. spectral width,
32K data arrays and 64 scans with 901 pulses applied every 15.2s to
allow for full relaxation of all protons. Trimethylsilyl propionic-
2,2,3,3,-d4 acid (TMSP; 0.5mmoll
 1 for cell PCA extracts and
1.1mmoll
 1 for media and lipids) was set to 0p.p.m. for chemical
shift reference and used as an external standard for metabolite
quantification.
13C-NMR spectra with proton decoupling were
recorded using the C3-lactate peak at 21p.p.m. as chemical shift
reference (spectral width was 150p.p.m., 16K data arrays and
20K scans applied every 3s). For absolute quantification of
13C
metabolites, calculations according to Zwingmann and Leibfritz,
(2003) were made.
31P-NMR spectra were obtained using the spectral width of
50p.p.m. and 16K data arrays, 6–10K scans applied every 3.5s.
Before
31P-NMR spectra were recorded, EDTA (100mmoll
 1) was
added to each PCA extract to complex divalent cations, and the pH
was adjusted to 7.2. Methylene diphosphonic acid (2mmoll
 1)i na
sealed capillary was used as chemical shift reference (18.6p.p.m.),
and as an external standard for metabolite quantification using
31P-NMR. All data were processed using the Bruker 1D-WINNMR
Software (Bruker Biospin).
To verify the metabolite assignments in extracts, two-dimen-
sional (2D)-H,C-HSQC (heteronuclear single quantum correlation)
was carried out. All 2D-measurements were performed using a
600MHz Bruker DRX spectrometer system (Bruker, Karlsruhe,
Germany). The experiments were acquired with 512 t1-increments
and 32 scans per increment. All 1D-NMR experiments were
performed at the Metabolomics NMR University of Colorado
Cancer Center Core.
HPLC/MS analysis
For the nucleotide concentration measurements (ATP, ADP,
NAD
þ, AMP, UTP and CTP), an Agilent 1100LC system coupled
to an ESI/MSD detector was used. The cells (10
8 cells each) were
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sextracted using PCA (see above), and the high-performance
liquid chromatography/mass spectrometry (HPLC/MS) method
was validated (Klawitter et al, 2007). The assay was linear
from a 10 to 1000pmol nucleotide amount on the column using
N6-(aminohexyl)-adenosine-5030-diphosphate (Sigma-Aldrich, St Louis,
MO, USA) as an internal standard. The cell extracts were diluted 1:5,
so that the measured concentrations fell within the linear range of
quantification.
Intra- and extracellular imatinib concentrations were deter-
mined using a validated LC/MS/MS assay. Briefly, after ultrasonic
treatment and protein precipitation with methanol/60mM zinc
sulphate (80/20 v/v), the cell samples (each 10
7 cells) were
extracted on-line. After activation of the column switching-valve,
the extracts were back-flushed onto the analytical column (Luna
C18, 50 4.6mm, 5mm, Phenomenex, Torrance, CA, USA). The
HPLC system, interfaced with a triple quadrupole MS (API4000,
Applied Biosystems, Foster City, CA, USA), was run in positive
multiple reaction monitoring (MRM) mode. Peak area ratios
obtained from the MRM mode of the mass transition for imatinib
(m/z 494-394) and from the internal standard trazadone (Sigma-
Aldrich; m/z 372-176) were used for quantification. The lower
limit of quantification was 0.03ngml
 1 cell homogenate from 10
7
cells, and the assay was linear between 0.03 and 75ngml
 1.
Interday accuracy was between 90–110% of the nominal
concentrations, and interday precision was always equal to or
better than 10%. No significant ion suppression or other matrix
interference was detected. Samples were stable in the autosampler
at þ41C for at least 24h, and the drug was stable in cell
homogenates for at least three freeze-thaw cycles. All HPLC/MS
analyses were performed at the Clinical Nutrition Research Unit
Mass Spectrometry Core (University of Colorado, Denver).
Statistical analysis
The number of observations was n¼3 or higher for all
experiments. All numerical data are presented as mean±s.d.
One-way analysis of variance (Estanyol et al, 1999) was used to
determine differences among groups (untreated vs time-course
treated). The significance level was set at Po0.05 for all tests
(SigmaPlot-version 9.01, Systat Software, Point Richmond, CA and
SPSS version 14.0, SPSS Inc., Chicago, IL, USA).
RESULTS
Cell proliferation and cell death
Following established protocols (Mahon et al, 2000; Melo and
Chuah, 2007), K562 cells were exposed to increasing concentra-
tions of imatinib to induce resistance against 1mM imatinib.
Exposure of K562 cells to 0.1mM imatinib for 96h led to a signi-
ficant change neither in cell proliferation nor in cell cycle distri-
bution. The time period between the second (0.2mM imatinib) and
third week of treatment (0.3mM imatinib) was marked by a
decreased cell proliferation rate ( 34% decrease in treated vs
untreated cells). Finally, 4 weeks of treatment with imatinib
reduced the number of viable cells to  46%, and the prolonged
incubation to 0.5mM imatinib (5 weeks) reduced it further
by 70%.
After staining with YoPro and PI, the living cells (Figure 1A–C,
bottom left corner) were non-fluorescent as assessed by flow
cytometry, although having the ability to exclude both dyes. Early
apoptotic cells that were labelled with YoPro, but still maintaining
the ability to exclude PI, were located in the bottom right corner.
Finally, apoptotic (upper right corner) and necrotic (upper left
corner) cells were both YoPro and PI
þ. If untreated, most of the
K562 cells were viable cells (bottom left corner) without significant
signs of apoptosis as can be seen on flow cytometry plots
(Figure 1A). After 96h of treatment with 0.1mM imatinib, apoptosis
was initiated and widespread with increasing incubation time and
dose (weekly increase by 0.1mM imatinib; Figures 1B and 2). After
4 weeks (0.4mM imatinib), 44% apoptotic cells were detected in
K562 cells (Figures 1C and 2).
Another method used for measurements of cell viability and
membrane stability was staining with Trypan blue. No increase in
the number of stained, dead cells occurred until 2 weeks. At this
time point, approximately 20% total dead cells were observed. This
confirmed the flow cytometry findings (Figure 2). Thereafter, the
number of dead cells increased exponentially. As aforementioned,
after 4 weeks, more then 46% of cells were dead.
Changes in Bcr-Abl protein expression and protein
phosphorylation
Incubation with imatinib significantly reduced the fluorescence
intensity of the p-tyr staining in K562 leukaemia cells. Western
blot analysis showed that the p-tyr band (at 210kDa) completely
disappeared after 2h of exposure to 0.1mM imatinib (Figure 3A).
Flow cytometry revealed a significant decrease to less than 30% of
the expression of controls after 96h of incubation (Po0.0001,
n¼3). Moreover, the level of the c-Abl protein was almost three-
fold higher than that in the controls after 24–48h (likely trying to
compensate for decreased tyrosine kinase activity), but decreased
to control values after 96h of treatment (Figure 3B).
Glucose metabolism after imatinib treatment
After 1 week of 0.1mM imatinib treatment, glucose metabolism in
K562 cells shifted from predominantly cytosolic glycolysis, as
indicated by decreased lactate production, towards the mito-
chondrial Krebs cycle, as indicated by elevated glutamine and
glutamate synthesis. As calculated from the
13C-NMR spectra of
cell extracts, the concentration of de novo produced [3-
13C]-lactate
decreased to  39% (Po0.05), indicating an inhibition of cytosolic
glycolytic activity. In parallel, mitochondrial Krebs cycle-derived
metabolite production increased by þ44% (Po0.05, n¼5;
Table 1A). Further treatment of K562 cells (2 weeks with 0.2mM
imatinib) almost completely inhibited glycolysis (
13C-lactate
concentration diminished to  85% from control, Po0.005, all
above n¼5) and Krebs cycle activity started to decline (Table 1A),
reaching its minimum of  54% from baseline (Po0.005, n¼3)
after 4 weeks (imatinib at 0.4mM; Table 1A). The inhibition of
glycolytic and later mitochondrial glucose metabolism resulted in
intracellular glucose accumulation, despite imatinib-mediated
decrease in glucose uptake from the media (see below).
Glucose uptake/lactate release
The time course of imatinib effects on glucose uptake and lactate
release was studied in the media of K562 cells treated with imatinib
(Table 1B). In treated cells, lactate export was already reduced 24h
after addition of imatinib, followed by decreased glucose uptake
after 48h (Table 1B). Impaired glycolytic activity of leukaemia cells
during treatment with imatinib led to extracellular and intra-
cellular glucose accumulation with a subsequent loss of lactate
export into the extracellular milieu of K562 cells (Table 1B). This
was the earliest metabolic effect observed in imatinib-treated cells
that started at 24h and reached its plateau after 96h of treatment
(see Table 1B).
Energy state after imatinib treatment
The increase in mitochondrial glucose metabolism during the first
week of treatment was accompanied by a higher energy state of
Bcr-Abl
þ K562 cells as indicated by
31P-NMR spectra of cell
extracts (Figure 4A). The cell energy balance (calculated as
Metabolism of imatinib-treated cells
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snucleoside triphosphate to nucleoside diphosphate (NTP/NDP)
ratio) increased from 6.7 in control to 9.4 after 1 week of imatinib
treatment (Po0.05, n¼4, Table 1A). From that point on, the energy
balance declined to control values after 2 weeks and reached  74%
of the control values after 4 weeks of treatment (Table 1A). This
went parallel with the activation of the apoptosis cascade. At the
same time, a noticeable decrease in phosphocreatine concentration
was observed and it reached its minimal value again after 4 weeks of
treatment (the signal was not detectable, Table 1A).
As the magnetic field employed for our
31P-NMR experiments
could not resolve specific trinucleotides, additional HPLC/MS
analyses were performed to determine concentrations of specific
nucleotides. The results are presented in Figure 4B. These analyses
confirmed the
31P-NMR results. Imatinib-treated cells accumulated
high-energy phosphates during the first week of treatment.
Thereafter, the tri-/dinucleotides ratio decreased and remained
low after 2 weeks of treatment.
High-performance liquid chromatography/mass spectrometry
analyses of NAD
þ concentrations showed a significant decrease
after just 96h of incubation in imatinib-treated cell lines and an
even further reduction with increasing treatment duration and drug
concentration (which can be explained by decreased glycolytic
activity). After 2 weeks of imatinib treatment, the intracellular
NAD
þ concentration decreased from 1.3 to 0.5mmoll
 1 per 10
7
cells and remained at this low level up to 4 weeks of treatment.
Changes in phospholipid metabolism
Another significant difference in the metabolic response of
imatinib-treated K562 cells compared with controls was a decrease
of PC and phosphatidylcholine (PtdCho). Phosphocholine (the
precursor of PtdCho, the major phospholipid in the cell membrane)
104 A
103
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100 101 102
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103 104 100 101 102 103 104
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103
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103 104
Figure 1 Flow cytometry plots of K562 cells: (A) untreated cells (control); (B) treatment with 0.1mM imatinib for 1 week; and (C) treatment with
increasing imatinib concentrations for 4 weeks (0.1mM imatinib increase per week; end concentration 0.4mM). In each plot, four quadrants with different cell
viabilities were distinguished: bottom left, living cells; upper left, necrotic cells; bottom right, early apoptotic; upper right, apoptotic cells. In all cells, 3–8%
necrotic cells were observed because of the staining procedures.
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Figure 2 Time-dependent and imatinib-concentration-dependent num-
ber of apoptotic and necrotic cells in K562 cells. The data are presented as
meansþs.d. of three independent flow cytometry experiments and are
given as % of cell population (set at 100%); significance levels: *Po0.05;
**Po0.005; ***Po0.001.
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sdecreased by  25% in the first week (Po0.05, n¼5) and further by
 47% in the following week of treatment with imatinib (Po0.001,
n¼4; Table 1A), as calculated from the
31P-NMR spectra of PCA cell
extracts (Figure 4A). The PC concentration of about 50% of controls
remained at the same level in the following 2 weeks of treatment.
The decrease in PC resulted in overall declined ratios of
phosphomonoester (PME) to phosphodiester (Pozzi et al, 2004).
These are surrogate markers for phospholipid-pool turnover ( 38
and  52% of control after 2 and 4 weeks, respectively, Po0.05).
Changes in PtdCho concentration, the major phospholipid in
the cell membrane, reflected the same profiles as measured by
1H-NMR of lipid fractions. The PtdCho concentration decreased by
 13% of control (although not significant) after the first week and
continued to decrease by  24% (Po0.05) after 2 weeks, with a
minimum of  50% of control observed after 4 weeks of treatment
(Po0.005, all n¼3).
Changes in neutral lipids and fatty acids
With increasing apoptosis rate, increased signal intensity of PUFAs
was observed after 2 and 4 weeks of treatment (þ50 and þ81%
from control, respectively, Po0.05). In addition, the concentration
of methylene/methyl (CH2/CH3) resonances of fatty-acid chains
increased as well (CH2: þ38 and þ72% of control after 2 and 4
weeks, both Po0.001 with n¼3 and CH3: þ20% (not significant)
and þ35% (Po0.05) of control after 2 and 4 weeks, respectively,
n¼3). De novo diacylglycerol (DAG) and TAG syntheses were not
studied, but the integration of the TAG signal in
1H-MRS spectra of
lipids revealed that its total concentration increased by þ21 and
þ81% of controls following 2 and 4 weeks of imatinib treatment
(n¼3, Po0.05, respectively).
Intra- and extracellular imatinib concentrations
Intracellular imatinib concentrations did not significantly change
between 24 and 72h of treatment. After 96h, accumulation of
imatinib was seen in K562-treated cells (Table 2). After the first week,
the cell media was changed and fresh 0.2mM imatinib was added. The
total imatinib concentration was again measured at the end of 2
weeks (calculated as the sum of intra- and extracellular concentra-
tions), and showed that 20% of imatinib had degraded or had been
metabolised after this period of time. The same procedure was
A
c 30 min 2 h 4 h 24 h 48 h 96 h c
210 kDa
42 kDa
30 min 2 h 4 h 24 h 48 h 96 h
B
Figure 3 Western blot (A) of p-tyr expression in K562-treated cells in the first 96h of imatinib treatment (0.1mM). Changes in c-Abl protein expression
were also assessed by western blotting (B). All western blots were carried out in triplicate.
Table 1A Absolute intracellular concentrations (nmolg
 1 cell weight) of
13C-glucose and its intermediates (lactate and TCA cycle intermediates), high
energy phosphates (PCr, NTP and NDP), NAD
+ (mmoll
 1 per 10
7 cells), phospholipids (phosphatidylcholine and phosphocholine), acetate and
polyunsaturated fatty acids (PUFA) and their ratios (NTP/NDP and PME/PDE) calculated from K562 cell extracts as assessed by
1H-,
13C- and
31P-NMR
A Control 0.1lM 1 week 0.2lM 2 weeks 0.4lM 4 weeks
13C-lactate 1041.2±376.6 639.1±145.4* 153.8±62.3* 210.1±36.7**
TCA cycle intermediates 313.2±69.5 448.4±93.3* 299.1±41.1 143.8±66.3**
Glucose intracell 69.7±13.9 204.1±76.4* 192.9±43.2* 213.0±85.6**
(NTP/NDP) 6.67±1.50 9.42±0.94* 6.66±0.96 1.75±0.60**
NAD
+ 1.32±0.46 0.74±0.30** 0.54±0.27*** 0.41±0.22***
PCr 540.2±247.1 230.2±50.2* 270.1±9.32*** ND
PC 1448.3±205.2 1086.4±53.4* 765.1±82.0*** 737.5±35.4***
PtdCho 2351.3±432.3 2052.1±411.2 1794.3±293.3* 118.6±225.3**
(PME/PDE) 4.31±1.52 4.01±1.01 2.67±0.13* 2.07±0.56*
Acetate 413.1±81.8 368.7±149.5 668.9±247.2 411.0±181.2
PUFA 2512.3±264.3 3094.2±445.3 3185.3±293.4* 4784.7±227.5***
Abbreviations: NAD
+¼nicotineamide adenine dinucleotide; ND¼not detectable; NDP¼nucleoside diphosphate; NTP¼nucleoside triphosphate; PC¼phosphocholine;
PCr¼phosphocreatine; PDE¼phosphodiester; PME¼phosphomonoester; PtdCho¼phosphatidylcholine; PUFA¼polyunsaturated fatty acids; TCA¼tricarboxylic acid.
Values are presented as means±s.d. of 3–5 independent experiments (control and 1-week experiments were performed with n¼5; 2- and 4-week experiments with n¼3).
Significance levels: *Po0.05; **Po0.005; ***Po0.001 were determined by ANOVA (with post hoc pairwise multiple comparison Tukey-test).
Table 1B Absolute concentrations of
13C-labelled extracellular glucose and lactate (mmoll
 1 per 10
7cells) in K562 cell media as calculated from
1H-NMR
spectra
B Control 0.1lM 24h 0.1lM 48h 0.1lM 96h 0.2lM 2 weeks 0.4lM 4 weeks
Glucose extracell 2.23±0.19 2.39±0.08 2.89±0.12** 3.80±0.15*** 3.91±0.26*** 4.53±0.76***
Lactate extracell 0.303±0.033 0.185±0.019** 0.106±0.004*** 0.037±0.005*** 0.030±0.001*** 0.021±0.013***
Results are means±s.d. (all groups n¼5). Significance levels: **Po0.005; ***Po0.001 were determined by ANOVA (with post hoc pairwise multiple comparison Tukey-test).
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srepeated after 3 and 4 weeks. At the end of 4 weeks, the concentration
of imatinib was 13% less than that of the amount added.
Expression of p-glycoprotein
Assessment of the effects of incubation time and imatinib
concentrations showed that K562 cells were not subject to any
changes in p-glycoprotein expression.
DISCUSSION
The discovery and development of imatinib has shown that it is
possible to produce rationally designed, molecular-targeted drugs
for treatment of a specific cancer. Such designed compounds can
affect not only one, but several targets, allowing for therapeutic
efficacy in several diseases. One of the major concerns with
imatinib treatment is the development of drug resistance. Earlier
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Figure 4 (A) Representative
31P-NMR spectra of K562 cell extracts. Cells were incubated with 0.1mM imatinib for 96h or 1 week and with 0.2mM
imatinib for 2 weeks, and compared with untreated controls. (B) Concentration ratios of high-energy phosphates as calculated from the HPLC/MS data of
K562 cell extracts. Energy charge was calculated as ((ATPþ0.5*ADP)/(AMPþADPþATP)). The values were calculated per number of cells ( 10
7) and
are given as % of controls set to 100% and represent meansþs.d. of three independent experiments. Significance levels: *Po0.05; **Po0.005;
***Po0.001. Peak assignment: PC¼phosphorylcholine; PE¼phosphorylethanolamine, Pi¼inorganic phosphate; GPC¼glyceryl-PC; GPE¼glycerylpho-
sphoethanolamine; X¼other phosphodiesters; PCr:¼phosphocreatine; NAD(H)¼nicotine amide adenine dinucleotide; NTP¼nucleotide triphosphates;
NDP¼nucleotide diphosphates. The chemical shift assignment was based on the methylene diphosphonic acid (MDP) signal at 18.6p.p.m.
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sresearch and clinical reports have indicated that the changes in
glucose metabolism may be related to, or even be predictive of, the
development of imatinib resistance (Serkova and Boros, 2005).
In this study, cellular metabolic responses to imatinib treatment,
including mitochondrial activity and glucose utilisation, energy
production and membrane turnover were investigated in a time-
dependent matter following the cells on their path in becoming
resistant to imatinib (for a summary of these effects, please refer to
Figure 5). The imatinib concentration chosen (0.1mM) had
successfully been used in earlier studies (Gottschalk et al, 2004).
This concentration was confirmed not to cause cytotoxic effects
during short-term administration (up to 96h). However, long-term
treatment (from 1 to 4 weeks) with a dose-escalation (0.1mM
imatinib per week) caused significantly higher apoptosis rates, and
after 4 weeks, 46% of the treated cells were dead. The exact time
course for imatinib-mediated metabolic changes is presented in
Figure 5, with initial glycolysis inhibition, followed by decrease in
glucose uptake, changes in mitochondrial TCA cycle derivatives
and energy production. Secondary changes were related to
membrane composition as seen from lipid and phospholipid
turnover (Henke et al, 1998).
Tumour cells exhibit elevated glycolysis rates even in the
presence of oxygen, the so-called Warburg effect (Warburg, 1956).
Increased expression of the glucose transporter, Glut-1, and
increased hexokinase activity seem to be associated with the
acceleration of glycolysis in tumours (Asano et al, 2000). Studies in
gastrointestinal stromal tumour patients have shown a rapid
decrease in fluorinated deoxyglucose (FDG) uptake, sometimes as
early as 24h after administration of imatinib (Van den Abbeele
and Badawi, 2002). Earlier studies have also reported that imatinib
regulates glucose flux through downregulation and translocation
of Glut-1 transporters from the cell membrane into the cytoplasm
in human leukaemia cells (Boren et al, 2001).
When treated with imatinib, leukaemia cells showed complete
and rapid inhibition of their tyrosine kinase activity (2h), followed
immediately by decreased glycolysis rates (24h). This is consistent
with the reversal of the Warburg effect. The suppression of
glycolysis resulted in decreased [1-
13C]glucose uptake from the
incubation media at 48h. This supported earlier findings
(Gottschalk et al, 2004). Although the [3-
13C]-lactate concentration
decreased, a simultaneous increase in C4-glutamate production
occurred during the first week of the observation period.
Production of high-energy phosphates (NTP) was elevated most
likely because of increased mitochondrial energy production.
These observations and the suggestion that imatinib stimulates
mitochondrial metabolism and reduces anaerobic glycolysis in
Bcr-Abl
þ leukaemia cells in the first 96h of treatment confirmed
the results reported by Gottschalk et al (2004).
When cells are exposed to cytostatic agents, there are two major
types of cell death: apoptosis and necrosis. Cell shrinkage, DNA
damage, chromatin condensation and blebbing of the plasma and
alteration of plasma membrane phospholipid organisation with
phosphatidylserine externalisation are major characteristics of
apoptosis (Williams, 1991; Wood and Youle, 1994). Necrosis is
generally characterised by swelling of cells and mitochondria,
scattered chromatin condensation and loss of plasma membrane
integrity because of an overwhelming physical cell injury
(Williams, 1991; Nicotera and Leist, 1997).
In the time period between 96h and 2 weeks of treatment, the
antiproliferative and proapoptotic properties of imatinib were
Table 2 Intracellular imatinib concentrations in K562 as calculated based on HPLC-MS/MS data
24h 48h 72h 96h 2 weeks 4 weeks
Imatinib dose 0.1mM 0.1mM 0.1mM 0.1mM 0.2mM 0.4mM
Imatinib intracell 0.015±0.003 0.015±0.001 0.019±0.005 0.018±0.002* 0.035±0.005** 0.065±0.009***
The values were calculated as mM imatinib per 10
7 cells and represent means±s.d. of four independent experiments. Statistical significance: *Po0.05; **Po0.005; ***Po0.001
when values were compared with the 24-h value(s). Comparison by ANOVA indicated statistically significant differences with Po0.001.
Cell proliferation
Cell death
24 h 48 h 96 h 2 weeks 4 weeks
p-Tyr
inhibition
c-Abl
increase
c-Abl
decrease
Glycolysis
decrease Glycolysis
inhibition
TCA cycle
increase TCA cycle
decrease
Lactate
export
Glucose
uptake
Energy state
increase
1 week
Energy state
decrease
NAD+
decrease
PC and PtdCho
decrese
PUFA
increase
Imatinib
accumulation
Figure 5 Summary of time-dependent effects of imatinib on metabolism of human Bcr-Abl
þ K562 cells. NAD
þ ¼nicotinamide adenine dinucleotide;
PC¼phosphocholine; PtdCho¼phosphatidylcholine; PUFA¼polyunsaturated fatty acids; TCA¼tricarboxylic acid.
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srevealed in our cell model. After the first week of treatment,
decreased cell proliferation rate and increased number of apoptotic
cells became detectable and were enhanced with longer incubation
times and higher imatinib concentrations. Short-term incubation
with 0.1mM imatinib led to an increase in mitochondrial activity
and energy balance and/or charge. The maxima were reached after
1 week. Thereafter, both mitochondrial activities and energy
charge started to decrease. After 96h, the first signs of apoptosis
were observed, the cells were highly active and have maintained
their elevated mitochondrial activity. This is consistent with the
literature, in which it is known that the apoptotic process demands
high energy for its development (Eguchi et al, 1997; Zamaraeva
et al, 2005).
Recent studies showed that cells undergoing apoptosis show the
same or even better energy status as long as the cells maintained a
highly active metabolism (such as various biosynthesis processes
including lipid biosynthesis, DNA fragmentation and so on;
Budd et al, 2000; Zamaraeva et al, 2005). As apoptosis progresses,
energy metabolism declines rapidly. In our case with increasing
number of apoptotic and dead cells, a marked decrease in PCr was
observed with a subsequent decrease in NTP concentrations.
Similar observations were made by Henke (1996), whose
investigations on miltefosine-induced apoptosis revealed a ‘stable’
NTP state as long as the cells maintained a highly active
metabolism. In addition to the energy state, decreased NAD
þ
concentration may also serve as early indicators for ongoing
imatinib-induced apoptosis. Earlier studies have shown that other
antitumour agents initiate the apoptotic cascade by decreasing
NAD
þ concentrations (Wosikowski et al, 2002).
Phosphocholine, a major precursor for membrane synthesis, is
known to increase in rapidly proliferating cancer cells, including
leukaemia cells (Franks et al, 2002; Ackerstaff et al, 2003). Its
reduction was significant after the first week and even enhanced
after 2–4 weeks of imatinib treatment. The reduction in PC is
within the response of other cell types and tumours to treatment as
described earlier (Glunde and Serkova, 2006). In addition, lower
PC concentrations led to decreased PtdCho concentrations.
Phosphatidylcholine is the major phospholipid component of cell
membranes and is necessary for the structure and function of all
cells and is crucial for sustaining life (Kent, 1995). The observation
that the concentration of PtdCho decreased with advancing
apoptosis stages has been reported earlier (Engelmann et al,
1996; Glunde et al, 2002).
The increase of CH2 and CH3 resonances of free-fatty acid
chains, as well as the accumulation of PUFAs, represents two other
characteristics associated with ongoing cell death processes
(Blankenberg et al, 1997; Griffin et al, 2003). This change in the
degree of unsaturation of fatty acid chains, together with the
detected neutral lipid accumulation and the observation of a
significant drop in PtdCho, could result from either activated
PtdCho catabolism or inactivated PtdCho anabolism. Considering
the PtdCho catabolic pathway, two options are possible. The first
option involves the activity of phospholipase A2 to produce lyso-
PtdCho (Hakumaki et al, 1999), which in turn can be hydrolysed
into free-fatty acids and GPC. In our experimental setup, we did
not observe an increase in GPC, making this catabolic pathway
more unlikely. The second catabolism pathway involves the action
of PtdCho-specific phospholipase C. In our system, this is also not
very likely as the reaction product, PC, does not increase, but
drops after imatinib treatment. Considering the PtdCho anabolic
pathway, as the cells are preparing to die, they could be reducing
their uptake of choline; hence, less PtdCho would be synthesised.
This would lead to an accumulation of DAGs, which could then
be converted to TAGs to prevent the disruption of cellular
metabolism. This is most likely the cause for the accumulation of
TAGs in our cells and the most likely explanation for the decrease
in PtdCho and accumulation of neutral lipids and fatty acids. The
accumulated fatty acids can enter the mitochondrial or perox-
isomal b-oxidation pathway, in which they are broken down to
acetyl-CoA or acetate. The overall concentration of acetate, the end
product of peroxisomal b-oxidation, was not significantly changed
upon imatinib treatment. However, it is possible that the lipid
synthesis and cycling may have allowed for peroxisomal
b-oxidation and energy production to replace mitochondrial
b-oxidation during imatinib exposure.
The generally accepted action of ABCB1 (MDR1) is to reduce
intracellular drug accumulation through p-glycoprotein-mediated
efflux, thus reducing drug concentrations at the intracellular
effector sites. K562 cells, however, did not reveal any changes in
p-glycoprotein expression. Increased intracellular concentrations
of imatinib can be explained by a dose-escalating regimen as well
as by membrane changes detected by NMR. Studies have shown
that apoptosis, as detected in our imatinib-treated cells, leads to
changes in membrane fluidity and porosity, which in turn go
parallel with a reduction in p-glycoprotein function (Ferte, 2000;
Kok et al, 2000).
In summary, we studied the time-dependent effects of imatinib
on human Bcr-Abl
þ K562 cells over an observation period of 4
weeks. Initially, we observed a shift from energy production by
anaerobic glycolysis to mainly mitochondrial oxidation. Later
metabolite changes reflected apoptosis and, at an even later stage,
necrosis. Each of these imatinib-induced changes resulted in
characteristic intracellular metabolite patterns (Figure 5) and
showed good correlation with molecular changes such as protein
expression. Therefore, the use of multi-NMR spectroscopy in cell
extracts can help to evaluate the mode of action of anticancer
drugs on the molecular level. On the basis of our results, it seems
reasonable to assess in future studies to which extent these results
can be translated into diagnostic tools for monitoring imatinib
therapy.
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